TY  - JOUR
A1  - Gerhard‐Hartmann, Elena
A1  - Jöhrens, Korinna
A1  - Schinagl, Lisa‐Marie
A1  - Zamó, Alberto
A1  - Rosenwald, Andreas
A1  - Anagnostopoulos, Ioannis
A1  - Rosenfeldt, Mathias
T1  - Epstein–Barr virus infection patterns in nodular lymphocyte‐predominant Hodgkin lymphoma
JF  - Histopathology
N2  - Aims
To investigate Epstein‐Barr virus (EBV) latency types in 19 cases of EBV‐positive nodular lymphocyte‐predominant Hodgkin lymphoma (NLPHL), as such information is currently incomplete.
Methods and results
Immunohistochemistry (IHC) for CD20, CD79a, PAX5, OCT2, CD30, CD15, CD3 and programmed cell death protein 1 was performed. For EBV detection, in‐situ hybridisation (ISH) for EBV‐encoded RNA (EBER) was employed combined with IHC for EBV‐encoded latent membrane protein (LMP)‐1, EBV‐encoded nuclear antigen (EBNA)‐2, and EBV‐encoded BZLF1. In 95% of the cases, neoplastic cells with features of Hodgkin and Reed–Sternberg (HRS) cells were present, mostly showing expression of CD30. In all cases, the B‐cell phenotype was largely intact, and delineation from classic Hodgkin lymphoma (CHL) was further supported by myocyte enhancer factor 2B (MEF2B) detection. All tumour cells were EBER‐positive except in two cases. EBV latency type II was most frequent (89%) and type I was rare. Cases with latency type I were CD30‐negative. Five cases contained some BZLF1‐positive and/or EBNA‐2‐positive bystander lymphocytes.
Conclusions
As HRS morphology of neoplastic cells and CD30 expression are frequent features of EBV‐positive NLPHL, preservation of the B‐cell transcription programme, MEF2B expression combined with NLPHL‐typical architecture and background composition facilitate distinction from CHL. EBER ISH is the method of choice to identify these cases. The majority present with EBV latency type II, and only rare cases present with latency type I, which can be associated with missing CD30 expression. The presence of occasional bystander lymphocytes expressing BZLF1 and/or EBNA‐2 and the partial EBV infection of neoplastic cells in some cases could indicate that EBV is either not primarily involved or is only a transient driver in the pathogenesis of EBV‐positive NLPHL.
KW  - EBV
KW  - Hodgkin lymphoma
KW  - latency type
KW  - NLPHL
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-276327
VL  - 80
IS  - 7
SP  - 1071
EP  - 1080
ER  - 
TY  - JOUR
A1  - Rosenfeldt, Mathias T.
A1  - Hartmann, Elena M.
A1  - Leng, Corinna
A1  - Rosenwald, Andreas
A1  - Anagnostopoulos, Ioannis
T1  - A case of nodular lymphocyte predominant Hodgkin lymphoma with unexpected EBV-latency type
JF  - Annals of Hematology
N2  - No abstract available.
KW  - nodular lymphcyte
KW  - Hodgkin lymphoma
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-232571
SN  - 0939-5555
VL  - 100
ER  - 
TY  - JOUR
A1  - Zamò, Alberto
A1  - Gerhard-Hartmann, Elena
A1  - Ott, German
A1  - Anagnostopoulos, Ioannis
A1  - Scott, David W.
A1  - Rosenwald, Andreas
A1  - Rauert-Wunderlich, Hilka
T1  - Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series
JF  - Virchows Archiv
N2  - The subclassification of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes has become mandatory in the 2017 update of the WHO classification of lymphoid neoplasms and will continue to be used in the WHO 5\(^{th}\) edition. The RNA-based Lymph2Cx assay has been validated as a reliable surrogate of high-throughput gene expression profiling assays for distinguishing between GCB and ABC DLBCL and provides reliable results from formalin-fixed, paraffin-embedded (FFPE) material. This test has been previously used in clinical trials, but experience from real-world routine application is rare. We routinely applied the Lymph2Cx assay to day-to-day diagnostics on a series of 147 aggressive B-cell lymphoma cases and correlated our results with the immunohistochemical subclassification using the Hans algorithm and fluorescence in situ hybridization findings using break-apart probes for MYC, BCL2, and BCL6. The routine use of the Lymph2Cx assay had a high technical success rate (94.6%) with a low rate of failure due to poor material and/or RNA quality. The Lymph2Cx assay was discordant with the Hans algorithm in 18% (23 of 128 cases). Discordant cases were mainly classified as GCB by the Hans algorithm and as ABC by Lymph2Cx (n = 11, 8.6%). Only 5 cases (3.9%) were classified as non-GCB by the Hans algorithm and as GCB by Lymph2Cx. Additionally, 5.5% of cases (n = 7) were left unclassified by Lymph2Cx, whereas they were defined as GCB (n = 4) or non-GCB (n = 3) by the Hans algorithm. Our data support the routine applicability of the Lymph2Cx assay.
KW  - diffuse large B-cell lymphoma
KW  - Hans algorithm
KW  - Lymph2Cx assay
KW  - cell of origin
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324686
VL  - 481
IS  - 6
ER  -